Cell Surgical Network

What Cell Surgical Network does

Cell Surgical Network (CSN) is a private regenerative medicine clinical research organization founded in 2012 by Dr. Mark Berman and Dr. Elliot B. Lander, headquartered in Rancho Mirage, California. The company operates a franchise-style network of 80+ affiliated treatment centers across the United States and at least 10 international markets — including Australia, Canada, China, Europe, India, Japan, South Africa, Thailand, and Turkey — that deploy adipose-derived stromal vascular fraction (SVF) under IRB-approved investigational protocols for inflammatory and degenerative conditions ranging from orthopedic and neurological (MS, Parkinson's, ALS, stroke) to autoimmune (lupus, rheumatoid arthritis, Crohn's), cardiac/pulmonary (asthma, COPD), urology, and ophthalmology indications.

The core technology is a closed sterile system that isolates 10–40 million mesenchymal stem cells from approximately 2 ounces of liposuctioned fat in about 90 minutes, enabling same-day autologous deployment under local anesthesia without cell culturing. CSN monetizes via patient-funded cash-pay procedures (insurance generally does not cover investigational stem cell therapy), affiliate credentialing through the co-founded International Cell Surgical Society (ICSS), and a downstream cryobanking service called Cells On Ice operated in partnership with American CryoStem.

The business model carries material regulatory risk: the FDA filed suit seeking a permanent injunction against CSN by classifying autologous SVF as a drug, and issued a Warning Letter to banking partner American CryoStem in January 2018. CSN operates as a private corporation with 11–50 employees and does not publicly disclose revenue, funding history, or detailed financials.

Name

Cell Surgical Network

Legal name

Cell Surgical Network Corporation

Website

https://stemcellrevolution.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Cell Surgical Network is a private regenerative medicine organization operating a global franchise network of 80+ affiliate clinics that perform same-day, patient-funded adipose-derived SVF stem cell deployment under IRB-approved investigational protocols for inflammatory and degenerative conditions.

Ownership category

akta.pro rank

Product category

Regenerative Medicine / Stem Cell Therapy

NAICS

Offices of Physicians (62111)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ)

Keywords

• Regenerative medicine treatments
• Adipose stem cell therapy
• Stromal vascular fraction
• Autologous cell therapy
• Investigational stem cells

Headquarters

HQ city

Rancho Mirage

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Patient-Funded Investigational Treatments: Treatments are patient-funded as investigational procedures under IRB-approved protocols. Fees cover SVF harvesting, preparation, and deployment which may include the use of advanced interventional radiology and fluoroscopy techniques. Insurance generally does not cover the actual cost since stem cell therapy is considered investigational. Cost varies depending on disease state and deployment type required.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Cell Surgical Network operates a network of affiliate physicians performing investigational autologous adipose-derived stromal vascular fraction (SVF) deployments for patients with inflammatory and degenerative conditions. The core procedure uses a closed sterile surgical method to isolate SVF from a patient's own fat via mini-liposuction, processing the cells within 90 minutes for same-day deployment under local anesthesia and IRB-approved protocols. Condition-specific deployment protocols cover urology, orthopedics, neurology, cardiac/pulmonary, autoimmune diseases, and ophthalmology indications.

Product overview

Cell Surgical Network operates as a multi-specialty stem cell treatment network providing investigational autologous adipose-derived stromal vascular fraction (SVF) deployment for clinical research. The core offering is a same-day closed surgical procedure that harvests fat via mini-liposuction, isolates SVF rich in mesenchymal stem cells and growth factors, and deploys it back into the patient within 90 minutes. They offer condition-specific deployment protocols across urology, cardiac/pulmonary, orthopedics, neurology, auto-immune diseases, and ophthalmology specialties. The network spans 80+ treatment centers domestically and internationally, with partner services for cell banking through Cells On Ice. All treatments are investigational and conducted under IRB-approved protocols.

Differentiator

Problem solved

Functional benefit

Brands

• Cells On Ice: Cryo-preservation and banking service for adipose derived stem cells, operated in collaboration with American CryoStem (ACS).
• SVF (Stromal Vascular Fraction)

Products and services

• Adipose Derived Stromal Vascular Fraction (SVF) Deployment Investigational autologous cell therapy using the patient's own adipose-derived stem cells, harvested via mini-liposuction and deployed the same day for various inflammatory and degenerative conditions. Intended for adult patients with conditions resistant to conventional treatments.
• Cellular Surgery Procedure (SVF Isolation and Same-Day Deployment) Closed surgical method using South Korean technology to isolate stromal vascular fraction from fat tissue, processed within 90 minutes for same-day deployment under local anesthesia. Delivered through CSN affiliate physicians across US and international centers.
• Condition-Specific SVF Deployment Protocols Specialized SVF deployment protocols for urology (Erectile Dysfunction, Interstitial Cystitis, Peyronie's Disease), cardiac/pulmonary (Asthma, COPD, Cardiomyopathy), orthopedics (knee, hip, shoulder, spine, ankle, elbow, hand), neurology (Multiple Sclerosis, ALS, Parkinson's, Stroke, Peripheral Neuropathy), autoimmune diseases (Lupus, Rheumatoid Arthritis, Crohn's, Scleroderma), and ophthalmology conditions. Targeted at individual patients with the relevant condition.
• Cells On Ice Cell Banking Service Cryo-preservation and banking service for adipose-derived stem cells operated in partnership with American CryoStem, enabling patients to store their SVF for repeat treatments or future use. Available to CSN patients who want to retain cells for later deployment.
• CSN Affiliate Physician Network Service Access to a global network of credentialed affiliate physicians providing standardized SVF treatments across 80+ treatment centers in the United States and internationally. Intended for patients who self-select a treatment center by state or country and complete a candidate application and medical consultation.

Quantifiable outcome

• Extraordinary safety record since starting treatments in 2010
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• International Cell Surgical Society (ICSS)coreStrategic or Co-development Partner · 1 January 2012US-based non-profit professional medical association dedicated to providing physician education, training and standards for the practice of cell-based medicine. Promotes transparency, oversight and patient safety through standards, IRB oversight, and ongoing physician education through conferences and newsletters.
• California Stem Cell Treatment CentercoreStrategic or Co-development Partner · 1 January 2010Founded by Dr. Mark Berman and Dr. Elliot Lander as a multi-specialty team to deploy SVF to patients under IRB governance. This was the precursor entity to Cell Surgical Network, established after developing the SVF isolation technology brought from Asia in 2010.

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Mesoblast: Mesoblast is a publicly listed cell therapy company commercializing mesenchymal stem cell products (e.g., remestemcel, rexlemestrocel) across inflammatory and cardiovascular indications overlapping CSN's protocol areas.
• Pluri (formerly Pluristem Therapeutics): Pluri develops placenta-derived cell therapies for inflammatory and hematologic conditions. Operates in the same regenerative cell-therapy space as CSN but uses allogeneic rather than autologous platforms.

Emerging players

• BioRestorative Therapies: BRTX is a clinical-stage biotech developing autologous stem cell therapies targeting disc/spine and metabolic indications, using similar adipose-derived cell platforms as CSN's SVF procedures.
• GID BIO: GID BIO develops point-of-care adipose-derived SVF processing systems, including the GID-SVF device platform used by regenerative medicine clinics, representing a potential technology peer to CSN's South Korean–sourced SVF isolation method.
• VetStem Biopharma: VetStem deploys autologous adipose-derived stem cell therapies through a network of trained veterinarians, mirroring CSN's affiliate-network model for human SVF but in the animal health market.
• Personalized Stem Cells: PSC develops autologous adipose-derived stem cell therapies under FDA IND protocols for orthopedic indications, overlapping CSN's SVF deployment in musculoskeletal conditions but pursuing formal trial pathways rather than self-pay clinics.

Direct peers

• Regenexx: Regenexx operates the largest US-affiliated network of interventional orthopedics clinics delivering autologous stem cell and platelet treatments. Closest comparable to CSN in model, network structure, and self-pay investigational positioning.
• StemGenex: StemGenex was a direct competitor running a multi-state autologous stem cell treatment clinic network using adipose- and bone-marrow-derived cells under similar investigational protocols before FDA enforcement actions curtailed its operations.

Others

• Cryo-Cell International: Cryo-Cell is a public cord blood and cellular storage company, comparable to CSN's Cells On Ice cryo-banking partnership for adipose-derived stem cells.
• ViaCord: ViaCord is a PerkinElmer-owned cord blood and tissue banking service. Relevant as a comparator for CSN's Cells On Ice autologous cell banking business model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/CellSurgicalNet

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cell Surgical Network